文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

mRNA-1273 或 Omicron 加强针在接种疫苗的猕猴中引发相似的 B 细胞扩增、中和反应，并提供针对 Omicron 的保护。

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.

机构信息

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Department of Pediatrics, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.

出版信息

Cell. 2022 Apr 28;185(9):1556-1571.e18. doi: 10.1016/j.cell.2022.03.038. Epub 2022 Mar 25.

DOI:10.1016/j.cell.2022.03.038
PMID:35447072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8947944/
Abstract

SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-matched vaccines would enhance protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing titers against D614G were 4,760 and 270 reciprocal ID at week 6 (peak) and week 41 (preboost), respectively, and 320 and 110 for Omicron. 2 weeks after the boost, titers against D614G and Omicron increased to 5,360 and 2,980 for mRNA-1273 boost and 2,670 and 1,930 for mRNA-Omicron, respectively. Similar increases against BA.2 were observed. Following either boost, 70%-80% of spike-specific B cells were cross-reactive against WA1 and Omicron. Equivalent control of virus replication in lower airways was observed following Omicron challenge 1 month after either boost. These data show that mRNA-1273 and mRNA-Omicron elicit comparable immunity and protection shortly after the boost.

摘要

SARS-CoV-2 的奥密克戎变体传播性很强，并且对基于原始刺突蛋白匹配疫苗的免疫具有很强的抗性。目前尚不清楚使用奥密克戎匹配疫苗进行加强免疫是否会增强保护效果。在这项研究中，接受了 0 周和 4 周 mRNA-1273 接种的非人类灵长类动物在第 41 周时使用 mRNA-1273 或 mRNA-Omicron 进行了加强免疫。第 6 周（峰值）和第 41 周（预加强）时，针对 D614G 的中和滴度分别为 4760 和 270 倒数 ID，针对奥密克戎的中和滴度分别为 320 和 110。加强免疫后 2 周，针对 D614G 和奥密克戎的滴度分别增加到 mRNA-1273 加强免疫的 5360 和 2980，mRNA-Omicron 的 2670 和 1930。针对 BA.2 的中和滴度也观察到了类似的增加。在接受任何一种加强免疫后，70%-80%的刺突特异性 B 细胞对 WA1 和奥密克戎具有交叉反应性。在加强免疫后 1 个月，奥密克戎挑战后下呼吸道的病毒复制得到了类似的控制。这些数据表明，mRNA-1273 和 mRNA-Omicron 在加强免疫后不久会产生相当的免疫和保护效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/b871e957ebd7/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3f57e3f3c87a/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3092a405383c/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c7a5e2877b45/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c1d294df44b4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7c425eea41d8/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/6673e860511b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1046d58b7dce/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/039bc640039a/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1333967e2c31/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/0481237684d6/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/90254aa33c2a/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/17b0701f19e3/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/46d0c4ea3a48/figs8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/8753f4aef60c/figs9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/07b2ab411265/figs10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7dde0cbf1f05/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/b871e957ebd7/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3f57e3f3c87a/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/3092a405383c/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c7a5e2877b45/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/c1d294df44b4/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7c425eea41d8/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/6673e860511b/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1046d58b7dce/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/039bc640039a/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/1333967e2c31/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/0481237684d6/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/90254aa33c2a/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/17b0701f19e3/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/46d0c4ea3a48/figs8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/8753f4aef60c/figs9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/07b2ab411265/figs10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/7dde0cbf1f05/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/8947944/b871e957ebd7/gr6_lrg.jpg

相似文献

[1]
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.

Cell. 2022-4-28

[2]
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.

J Virol. 2024-9-17

[3]
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.

Cell Rep Med. 2022-7-19

[4]
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.

Microbiol Spectr. 2023-6-15

[5]
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.

Front Immunol. 2023

[6]
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.

J Infect. 2023-9

[7]
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates.

Sci Immunol. 2023-10-27

[8]
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.

Cell. 2022-4-28

[9]
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.

mBio. 2024-2-14

[10]
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.

Vaccine. 2024-11-14

引用本文的文献

[1]
Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.

Nat Commun. 2025-6-25

[2]
Use of a Multiplex Immunoassay Platform to Investigate Multifaceted Antibody Responses in SARS-CoV-2 Vaccinees with and Without Prior Infection.

COVID. 2025-4

[3]
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.

Vaccines (Basel). 2025-4-17

[4]
Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection.

Cell Rep. 2025-4-22

[5]
Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models.

Front Immunol. 2025-3-17

[6]
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.

Signal Transduct Target Ther. 2025-2-26

[7]
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold.

J Nanobiotechnology. 2025-2-18

[8]
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.

PLoS Pathog. 2025-1-23

[9]
MHCI trafficking signal-based mRNA vaccines strengthening immune protection against RNA viruses.

Bioeng Transl Med. 2024-8-15

[10]
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.

Nat Commun. 2024-12-30

本文引用的文献

[1]
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.

EBioMedicine. 2022-9

[2]
Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.

PLoS One. 2022

[3]
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.

Nature. 2022-7

[4]
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.

Cell Host Microbe. 2022-6-8

[5]
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.

Trop Med Int Health. 2022-6

[6]
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.

Cell Rep Med. 2022-2-15

[7]
The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion.

Viruses. 2022-1-30

[8]
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.

Nat Med. 2022-5

[9]
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.

Nature. 2022-3

[10]
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.

N Engl J Med. 2022-3-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索